BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

222 related articles for article (PubMed ID: 14506661)

  • 1. Repifermin (keratinocyte growth factor-2) reduces the severity of graft-versus-host disease while preserving a graft-versus-leukemia effect.
    Clouthier SG; Cooke KR; Teshima T; Lowler KP; Liu C; Connolly K; Ferrara JL
    Biol Blood Marrow Transplant; 2003 Sep; 9(9):592-603. PubMed ID: 14506661
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Keratinocyte growth factor separates graft-versus-leukemia effects from graft-versus-host disease.
    Krijanovski OI; Hill GR; Cooke KR; Teshima T; Crawford JM; Brinson YS; Ferrara JL
    Blood; 1999 Jul; 94(2):825-31. PubMed ID: 10397751
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Granulocyte colony-stimulating factor-mobilized allogeneic stem cell transplantation maintains graft-versus-leukemia effects through a perforin-dependent pathway while preventing graft-versus-host disease.
    Pan L; Teshima T; Hill GR; Bungard D; Brinson YS; Reddy VS; Cooke KR; Ferrara JL
    Blood; 1999 Jun; 93(12):4071-8. PubMed ID: 10361103
    [TBL] [Abstract][Full Text] [Related]  

  • 4. IL-11 separates graft-versus-leukemia effects from graft-versus-host disease after bone marrow transplantation.
    Teshima T; Hill GR; Pan L; Brinson YS; van den Brink MR; Cooke KR; Ferrara JL
    J Clin Invest; 1999 Aug; 104(3):317-25. PubMed ID: 10430613
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Preimplantation factor reduces graft-versus-host disease by regulating immune response and lowering oxidative stress (murine model).
    Azar Y; Shainer R; Almogi-Hazan O; Bringer R; Compton SR; Paidas MJ; Barnea ER; Or R
    Biol Blood Marrow Transplant; 2013 Apr; 19(4):519-28. PubMed ID: 23266739
    [TBL] [Abstract][Full Text] [Related]  

  • 6. LPS antagonism reduces graft-versus-host disease and preserves graft-versus-leukemia activity after experimental bone marrow transplantation.
    Cooke KR; Gerbitz A; Crawford JM; Teshima T; Hill GR; Tesolin A; Rossignol DP; Ferrara JL
    J Clin Invest; 2001 Jun; 107(12):1581-9. PubMed ID: 11413166
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ex vivo fludarabine exposure inhibits graft-versus-host activity of allogeneic T cells while preserving graft-versus-leukemia effects.
    Giver CR; Montes RO; Mittelstaedt S; Li JM; Jaye DL; Lonial S; Boyer MW; Waller EK
    Biol Blood Marrow Transplant; 2003 Oct; 9(10):616-32. PubMed ID: 14569558
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pretreatment of donors with interleukin-18 attenuates acute graft-versus-host disease via STAT6 and preserves graft-versus-leukemia effects.
    Reddy P; Teshima T; Hildebrandt G; Williams DL; Liu C; Cooke KR; Ferrara JL
    Blood; 2003 Apr; 101(7):2877-85. PubMed ID: 12433681
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Graft-versus-leukemia effect and graft-versus-host disease can be differentiated by cytotoxic mechanisms in a murine model of allogeneic bone marrow transplantation.
    Tsukada N; Kobata T; Aizawa Y; Yagita H; Okumura K
    Blood; 1999 Apr; 93(8):2738-47. PubMed ID: 10194454
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Interleukin 18 preserves a perforin-dependent graft-versus-leukemia effect after allogeneic bone marrow transplantation.
    Reddy P; Teshima T; Hildebrandt G; Duffner U; Maeda Y; Cooke KR; Ferrara JL
    Blood; 2002 Nov; 100(9):3429-31. PubMed ID: 12384449
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hepatocyte growth factor preserves graft-versus-leukemia effect and T-cell reconstitution after marrow transplantation.
    Imado T; Iwasaki T; Kataoka Y; Kuroiwa T; Hara H; Fujimoto J; Sano H
    Blood; 2004 Sep; 104(5):1542-9. PubMed ID: 15100150
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Donor antigen-presenting cells regulate T-cell expansion and antitumor activity after allogeneic bone marrow transplantation.
    Li JM; Waller EK
    Biol Blood Marrow Transplant; 2004 Aug; 10(8):540-51. PubMed ID: 15282532
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Transplantation of Graft Anti-Host Cytotoxic T Lymphocytes Along with Allogeneic Bone Marrow Skips Macrophage-Induced Graft-Versus-Host Disease.
    Yoshida R; Yamana H; Hayashi M; Yasuda E; Shibayama Y; Hirose Y; Tanigawa N; Uchiyama K; Kubota T
    J Interferon Cytokine Res; 2021 Sep; 41(9):310-318. PubMed ID: 34543129
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Differential roles of IL-1 and TNF-alpha on graft-versus-host disease and graft versus leukemia.
    Hill GR; Teshima T; Gerbitz A; Pan L; Cooke KR; Brinson YS; Crawford JM; Ferrara JL
    J Clin Invest; 1999 Aug; 104(4):459-67. PubMed ID: 10449438
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effective graft-versus-leukemia effects independent of graft-versus-host disease after T cell-depleted allogeneic bone marrow transplantation in a murine model of B cell leukemia/lymphoma. Role of cell therapy and recombinant IL-2.
    Weiss L; Lubin I; Factorowich I; Lapidot Z; Reich S; Reisner Y; Slavin S
    J Immunol; 1994 Sep; 153(6):2562-7. PubMed ID: 8077666
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Differential use of Fas ligand and perforin cytotoxic pathways by donor T cells in graft-versus-host disease and graft-versus-leukemia effect.
    Schmaltz C; Alpdogan O; Horndasch KJ; Muriglan SJ; Kappel BJ; Teshima T; Ferrara JL; Burakoff SJ; van den Brink MR
    Blood; 2001 May; 97(9):2886-95. PubMed ID: 11313285
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Separation of antileukemic effects from graft-versus-host disease in MHC-haploidentical murine bone marrow transplantation: participation of host immune cells.
    Satake A; Inoue T; Kubo S; Taniguchi Y; Imado T; Fujioka T; Horiuchi M; Xu Y; Ikegame K; Yoshihara S; Kaida K; Tamaki H; Okada M; Okamura H; Ogawa H
    Int J Hematol; 2010 Apr; 91(3):485-97. PubMed ID: 20300982
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Interleukin-12 preserves the graft-versus-leukemia effect of allogeneic CD8 T cells while inhibiting CD4-dependent graft-versus-host disease in mice.
    Yang YG; Sergio JJ; Pearson DA; Szot GL; Shimizu A; Sykes M
    Blood; 1997 Dec; 90(11):4651-60. PubMed ID: 9373279
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Administration of interleukin-7 after allogeneic bone marrow transplantation improves immune reconstitution without aggravating graft-versus-host disease.
    Alpdogan O; Schmaltz C; Muriglan SJ; Kappel BJ; Perales MA; Rotolo JA; Halm JA; Rich BE; van den Brink MR
    Blood; 2001 Oct; 98(7):2256-65. PubMed ID: 11568014
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Effects of immature dendritic cells genetically modified to express sTNFR I on graft-versus-host disease (GVHD) and graft-versus-leukemia (GVL) in allogeneic bone marrow transplantation mice].
    Wang SH; Li DP; Zhang YJ; Zhang P; Zeng LY; Pan XY; Xu KL; Huang YH
    Zhonghua Xue Ye Xue Za Zhi; 2012 Feb; 33(2):88-93. PubMed ID: 22730654
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.